In Boston, strain engineering pioneer Ginkgo Bioworks Holdings has received notice from the New York Stock Exchange that the company’s average stock closing price was less than $1 per share over a consecutive 30 trading-day period—setting a countdown for Ginko to boost its price or be delisted.
Under the NYSE rules, Ginkgo now has a six-month period to regain compliance with the minimum price criteria.
Ginkgo said it intends to regain compliance with NYSE’s continued listing standards and is “considering all available options.”